Canadian researchers combine biology and magnetics to create anti-cancer nanorobots

The major side effects of delivering anti-cancer drugs, systemically, has warranted a more refined targeted approach. Now researchers say they have the answer by successfully targeting cancer cells with nanorobotic agents. The results may hold promise for refined chemotherapy in patients suffering from various cancers.

The research was a colloboration between the three French-Canadian institutes Polytechnique Montreal, Universite de Montreal and McGill University. The findings were published in the journal Nature Nanotechnology.

Systemic delivery of chemotherapeutic agents has long been used in oncology but also has major shortfalls: that of unspecific targeting of all tissue, which explains the harsh side-effects of such drugs on healthy tissue. Targeted medicine for this purpose has long been working hard to address this.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

Sylvain Martel who heads the research project, says their team’s nanorobotic agents can seek and find cancer cells, propelling themselves deep inside the tumors.

The nanorobotic agents consist of over a 100 million flagellated bacteria (giving them their self-propulsion), packaged with a chemotherapeutic payload that is released once the bacteria comes across an oxygen-deficient environment. 

Oxygen-deficient, or hypoxic, areas of the tumour are classically associated with resistance towards radiotherapy, amongst other traditions therapies. This approach ensures the drug is released at the site.

In designing the nanorobots, the researchers combine this biological system with magnets, which ensure the particles move in the direction of a magnetic field. In this way, the clinician or surgeon can directly control the transport of the drug to the tumour using a computer-guided magnetic field.

"This innovative use of nanotransporters will have an impact not only on creating more advanced engineering concepts and original intervention methods, but it also throws the door wide open to the synthesis of new vehicles for therapeutic, imaging and diagnostic agents," Martel said. "Chemotherapy, which is so toxic for the entire human body, could make use of these natural nanorobots to move drugs directly to the targeted area, eliminating the harmful side effects while also boosting its therapeutic effectiveness."

- here’s the release
- here’s the original article

Related Article:
Research provides new findings on drug delivery with nanoparticles

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.